

# ORGANS, BLOOD, TISSUES & CELLS IN THE EU



**BLOOD TRANSFUSION**  
25 MILLION / YEAR



**BONE MARROW TRANSPLANT**  
36 THOUSAND / YEAR



**ASSISTED REPRODUCTION CYCLES**  
920 THOUSAND (IN 2016)



**OTHER TISSUES :**  
HEART VALVES | SKIN | BONE | CORNEA



**PLASMA FOR MANUFACTURING MEDICINES**  
8,6 MILLION LITRES / YEAR

## FROM DONOR TO RECIPIENT



## EU ACTIONS



**SET SAFETY & QUALITY STANDARDS**



**MANAGE ALERT, VIGILANCE & TRACEABILITY SYSTEMS**



**COORDINATE AND EXCHANGE GOOD NATIONAL PRACTICES**




**FUND IMPROVEMENTS IN NATIONAL SYSTEMS**

@ [ec.europa.eu/health/blood\\_tissues\\_organ](https://ec.europa.eu/health/blood_tissues_organ)

Sources: CoE/ONT, ESHRE, EBMT, Commission Reports on Implementation, SEC Coding Platform, Annual Commission Summaries on Serious Adverse Reaction and Events (SARE), Marketing Research Bureau

Updated: December 2020



## ORGAN TRANSPLANTS

21 235  
KIDNEY



7 900  
LIVER



2 269  
HEART



2 136  
LUNG



### OTHERS

710  
PANCREAS

35  
SMALL BOWEL

HAND

FACE

**TOTAL IN 2019**  
34 THOUSAND

**55 THOUSAND**  
PATIENTS ON WAITING LIST ON 31/12/2019

### Shortcomings/gaps in legal framework for blood, tissues & cells

1. Technical rules no longer reflect science
2. Inadequate protection of some citizens, particularly donors
3. Variable oversight limits cross-border trust, exchange and access
4. Review of Clinical outcome data and more legal clarity needed to support innovation
5. Risks for supply disruptions are not addressed

(Source 2019 Evaluation)

REVISION WILL STRENGTHEN EU LEGISLATION

## MEDICAL CENTRES

1 400

BLOOD ESTABLISHMENTS

3 700

TISSUE ESTABLISHMENTS

800

ORGAN TRANSPLANT PROGRAMMES